Literature DB >> 27479179

Vascular events and risk factors for thrombosis in refractory anemia with ring sideroblasts and thrombocytosis.

M M Patnaik1, T L Lasho2, C M Finke2, C A Hanson3, R L King3, R P Ketterling4, N Gangat1, A Tefferi1.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27479179     DOI： 10.1038/leu.2016.216

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  8 in total

1.  Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis.

Authors:  Julien Broseus; Lourdes Florensa; Esther Zipperer; Susanne Schnittger; Luca Malcovati; Steven Richebourg; Eric Lippert; Jaroslav Cermak; Jyoti Evans; Morgane Mounier; José Maria Raya; François Bailly; Norbert Gattermann; Torsten Haferlach; Richard Garand; Kaoutar Allou; Carlos Besses; Ulrich Germing; Claudia Haferlach; Erica Travaglino; Elisa Luno; Maria Angeles Pinan; Leonor Arenillas; Maria Rozman; Maria Luz Perez Sirvent; Bernardine Favre; Julien Guy; Esther Alonso; Nuhri Ahwij; Andrés Jerez; Sylvie Hermouet; Marc Maynadié; Mario Cazzola; François Girodon
Journal:  Haematologica       Date:  2012-04-24       Impact factor: 9.941

2.  SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts.

Authors:  V Visconte; H Makishima; A Jankowska; H Szpurka; F Traina; A Jerez; C O'Keefe; H J Rogers; M A Sekeres; J P Maciejewski; R V Tiu
Journal:  Leukemia       Date:  2011-09-02       Impact factor: 11.528

3.  Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations.

Authors:  Sabine Jeromin; Torsten Haferlach; Sandra Weissmann; Manja Meggendorfer; Christiane Eder; Niroshan Nadarajah; Tamara Alpermann; Alexander Kohlmann; Wolfgang Kern; Claudia Haferlach; Susanne Schnittger
Journal:  Haematologica       Date:  2014-12-19       Impact factor: 9.941

4.  Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis).

Authors:  Tiziano Barbui; Guido Finazzi; Alessandra Carobbio; Juergen Thiele; Francesco Passamonti; Elisa Rumi; Marco Ruggeri; Francesco Rodeghiero; Maria Luigia Randi; Irene Bertozzi; Heinz Gisslinger; Veronika Buxhofer-Ausch; Valerio De Stefano; Silvia Betti; Alessandro Rambaldi; Alessandro M Vannucchi; Ayalew Tefferi
Journal:  Blood       Date:  2012-10-01       Impact factor: 22.113

Review 5.  Refractory anemia with ring sideroblasts and RARS with thrombocytosis.

Authors:  Mrinal M Patnaik; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2015-06       Impact factor: 10.047

6.  Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing.

Authors:  Mrinal M Patnaik; Terra L Lasho; Christy M Finke; Curtis A Hanson; Rebecca L King; Rhett P Ketterling; Naseema Gangat; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2016-04-04       Impact factor: 10.047

7.  SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value.

Authors:  Mrinal M Patnaik; Terra L Lasho; Janice M Hodnefield; Ryan A Knudson; Rhett P Ketterling; Guillermo Garcia-Manero; David P Steensma; Animesh Pardanani; Curtis A Hanson; Ayalew Tefferi
Journal:  Blood       Date:  2011-11-17       Impact factor: 22.113

8.  Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance.

Authors:  Mrinal M Patnaik; Terra L Lasho; Christy M Finke; Curtis A Hanson; Janice M Hodnefield; Ryan A Knudson; Rhett P Ketterling; Animesh Pardanani; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2013-01-18       Impact factor: 10.047
  8 in total
  7 in total

1.  Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms.

Authors:  Laura Palomo; Manja Meggendorfer; Stephan Hutter; Sven Twardziok; Vera Ademà; Irene Fuhrmann; Francisco Fuster-Tormo; Blanca Xicoy; Lurdes Zamora; Pamela Acha; Cassandra M Kerr; Wolfgang Kern; Jaroslaw P Maciejewski; Francesc Solé; Claudia Haferlach; Torsten Haferlach
Journal:  Blood       Date:  2020-10-15       Impact factor: 22.113

Review 2.  Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 Update on Diagnosis, Risk-stratification, and Management".

Authors:  Mrinal M Patnaik; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2019-01-24       Impact factor: 10.047

Review 3.  Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms.

Authors:  Michael J Hochman; Bipin N Savani; Tania Jain
Journal:  EJHaem       Date:  2021-07-19

Review 4.  Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management.

Authors:  Mrinal M Patnaik; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2017-03       Impact factor: 10.047

Review 5.  Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms.

Authors:  Laura Palomo; Pamela Acha; Francesc Solé
Journal:  Cancers (Basel)       Date:  2021-04-27       Impact factor: 6.639

Review 6.  Causes and Pathophysiology of Acquired Sideroblastic Anemia.

Authors:  Juan Jose Rodriguez-Sevilla; Xavier Calvo; Leonor Arenillas
Journal:  Genes (Basel)       Date:  2022-08-30       Impact factor: 4.141

7.  The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes.

Authors:  Tamara K Moyo; Jason H Mendler; Raphael Itzykson; Ashwin Kishtagari; Eric Solary; Adam C Seegmiller; Aaron T Gerds; Gregory D Ayers; Amy E Dezern; Aziz Nazha; Peter Valent; Arjan A van de Loosdrecht; Francesco Onida; Lisa Pleyer; Blanca Xicoy Cirici; Raoul Tibes; Klaus Geissler; Rami S Komrokji; Jing Zhang; Ulrich Germing; David P Steensma; Daniel H Wiseman; Michael Pfeilstöecker; Chiara Elena; Nicholas C P Cross; Jean-Jacques Kiladjian; Michael Luebbert; Ruben A Mesa; Guillermo Montalban-Bravo; Guillermo F Sanz; Uwe Platzbecker; Mrinal M Patnaik; Eric Padron; Valeria Santini; Pierre Fenaux; Michael R Savona
Journal:  BMC Cancer       Date:  2022-09-24       Impact factor: 4.638
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.